00570.HK
China Traditional Chinese Medicine Holdings Co. Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 1.35
+1.89%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 28.2B | 14.7B | 16.5B | 18.1B | 14.3B |
| Cost of Revenue | 14.8B | 7.7B | 8.7B | 8.8B | 7.1B |
| Gross Profit | 13.4B | 7.1B | 7.9B | 9.3B | 7.2B |
| Operating Expenses | |||||
| R&D Expense | 1.0B | 511.5M | 596.0M | 685.6M | 611.8M |
| SG&A Expense | 12.0B | 6.1B | 6.5B | 7.4B | 5.5B |
| General & Admin Expense | 1.7B | 1.1B | 1.1B | 1.0B | 944.4M |
| Selling & Marketing Expense | 7.6B | 5.0B | 5.4B | 6.4B | 4.6B |
| Other Expenses | 953.3M | 778.3M | 447.8M | (284.9M) | (26.2M) |
| Total Operating Expenses | 13.9B | 7.4B | 7.5B | 7.8B | 6.1B |
| Cost and Expenses | 28.7B | 15.0B | 16.2B | 16.7B | 13.2B |
| Operating Income (EBIT) | (498.7M) | (268.9M) | 335.6M | 1.4B | 1.1B |
| Non-Operating | |||||
| Interest Income | 83.5M | 34.7M | 47.7M | 65.3M | 67.3M |
| Interest Expense | 167.6M | 103.3M | 235.8M | 199.0M | 220.7M |
| Net Interest Income | (137.3M) | (68.7M) | (188.1M) | (133.8M) | (153.4M) |
| Other Non-Op Income/Expense | (755.3M) | (99.3M) | (172.5M) | (202.7M) | (224.2M) |
| Non-Operating Income (excl Interest) | (1.1B) | (719.7M) | (416.3M) | 3.7M | 3.5M |
| EBT (Pre-Tax Income) | (1.3B) | (368.2M) | 163.1M | 1.2B | 840.1M |
| Income Tax Expense | 220.6M | 89.9M | 142.3M | (171.5M) | 119.4M |
| Bottom Line | |||||
| Net Income | (1.3B) | (342.1M) | 54.1M | 1.3B | 764.5M |
| Earnings from Cont. Ops | (1.5B) | (458.1M) | 20.8M | 1.4B | 721.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.3B) | (342.1M) | 54.1M | 1.3B | 764.5M |
| Per Share | |||||
| Basic EPS | (HK$0.26) | (HK$0.07) | HK$0.01 | HK$0.26 | HK$0.15 |
| Diluted EPS | (HK$0.26) | (HK$0.07) | HK$0.01 | HK$0.26 | HK$0.15 |
| Revenue Per Share | HK$5.61 | HK$2.93 | HK$3.28 | HK$3.60 | HK$2.84 |
| Shares | |||||
| Basic Shares Outstanding | 5.0B | 5.0B | 5.0B | 5.0B | 5.0B |
| Diluted Shares Outstanding | 5.0B | 5.0B | 5.0B | 5.0B | 5.0B |
| Profitability Metrics | |||||
| EBITDA | 2.8B | 1.5B | 1.8B | 2.6B | 2.2B |
| D&A | 2.2B | 1.1B | 1.1B | 1.1B | 1.1B |
| EBIT | 650.8M | 450.8M | 751.9M | 1.4B | 1.1B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026